GB201614162D0 - Antibodies, uses thereof and conjugates thereof - Google Patents

Antibodies, uses thereof and conjugates thereof

Info

Publication number
GB201614162D0
GB201614162D0 GBGB1614162.4A GB201614162A GB201614162D0 GB 201614162 D0 GB201614162 D0 GB 201614162D0 GB 201614162 A GB201614162 A GB 201614162A GB 201614162 D0 GB201614162 D0 GB 201614162D0
Authority
GB
United Kingdom
Prior art keywords
conjugates
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1614162.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena (UK) Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Priority to GBGB1614162.4A priority Critical patent/GB201614162D0/en
Publication of GB201614162D0 publication Critical patent/GB201614162D0/en
Priority to ES17757849T priority patent/ES2983492T3/es
Priority to CN201780044227.8A priority patent/CN110049999B/zh
Priority to US16/303,600 priority patent/US11059903B2/en
Priority to JP2019502698A priority patent/JP7039554B2/ja
Priority to EP24173428.4A priority patent/EP4403226A3/en
Priority to PCT/GB2017/052448 priority patent/WO2018033749A1/en
Priority to EP17757849.9A priority patent/EP3500595B1/en
Priority to JP2022035222A priority patent/JP7486538B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GBGB1614162.4A 2016-08-18 2016-08-18 Antibodies, uses thereof and conjugates thereof Ceased GB201614162D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1614162.4A GB201614162D0 (en) 2016-08-18 2016-08-18 Antibodies, uses thereof and conjugates thereof
ES17757849T ES2983492T3 (es) 2016-08-18 2017-08-18 Anticuerpos anti-PSMA, usos de los mismos y conjugados de los mismos
CN201780044227.8A CN110049999B (zh) 2016-08-18 2017-08-18 抗psma抗体、其用途及其缀合物
US16/303,600 US11059903B2 (en) 2016-08-18 2017-08-18 Anti-PSMA antibodies, uses thereof and conjugates thereof
JP2019502698A JP7039554B2 (ja) 2016-08-18 2017-08-18 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート
EP24173428.4A EP4403226A3 (en) 2016-08-18 2017-08-18 Anti-psma antibodies, uses thereof and conjugates thereof
PCT/GB2017/052448 WO2018033749A1 (en) 2016-08-18 2017-08-18 Anti-psma antibodies, uses thereof and conjugates thereof
EP17757849.9A EP3500595B1 (en) 2016-08-18 2017-08-18 Anti-psma antibodies, uses thereof and conjugates thereof
JP2022035222A JP7486538B2 (ja) 2016-08-18 2022-03-08 抗ｐｓｍａ抗体、その使用及びそのコンジュゲート

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614162.4A GB201614162D0 (en) 2016-08-18 2016-08-18 Antibodies, uses thereof and conjugates thereof

Publications (1)

Publication Number Publication Date
GB201614162D0 true GB201614162D0 (en) 2016-10-05

Family

ID=57045541

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1614162.4A Ceased GB201614162D0 (en) 2016-08-18 2016-08-18 Antibodies, uses thereof and conjugates thereof

Country Status (7)

Country Link
US (1) US11059903B2 (OSRAM)
EP (2) EP3500595B1 (OSRAM)
JP (2) JP7039554B2 (OSRAM)
CN (1) CN110049999B (OSRAM)
ES (1) ES2983492T3 (OSRAM)
GB (1) GB201614162D0 (OSRAM)
WO (1) WO2018033749A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204477A1 (en) 2017-05-02 2018-11-08 Cornell University Methods and reagents for tumor targeting with greater efficacy and less toxicity
WO2019173324A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
WO2019191728A1 (en) * 2018-03-29 2019-10-03 Ambrx, Inc. Humanized anti-prostate-specific membrane antigen (psma) antibody drug conjugates
EP3994177A4 (en) * 2019-07-02 2023-09-20 Telix International Pty Ltd PSMA-BINDING ANTIBODIES WITH REDUCED AFFINITY FOR THE NEONATAL FC RECEPTOR
AU2020347171A1 (en) 2019-09-11 2022-03-10 The Trustees Of The University Of Pennsylvania Compositions and methods comprising prostate stem cell antigen (PSCA) chimeric antigen receptors (CARs)
WO2021098834A1 (zh) * 2019-11-22 2021-05-27 上海一宸医药科技有限公司 Psma抗体及其应用
CN110922486B (zh) * 2020-02-18 2020-05-22 和铂医药(上海)有限责任公司 一种分离的结合抗原psma的蛋白及其用途
WO2024182569A2 (en) * 2023-02-28 2024-09-06 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
JP2026507228A (ja) 2023-03-03 2026-02-27 アーセナル バイオサイエンシズ インコーポレイテッド Ｐｓｍａ及びｃａ９を標的とするシステム
CN116196428B (zh) * 2023-04-04 2025-04-04 上海愿智生物技术有限公司 一种药物组合物及其应用
CN116271081A (zh) * 2023-04-04 2023-06-23 上海愿智生物技术有限公司 一种抗体偶联药物yc1605及其药物组合物和应用
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
CN1294588C (zh) 1996-07-24 2007-01-10 皇家菲利浦电子有限公司 光盘录取装置
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
US20040136998A1 (en) 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
MX2007009878A (es) 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
CN101160324B (zh) * 2005-02-18 2013-04-24 米德列斯公司 缺乏岩藻糖残基的抗前列腺特异性膜抗原(psma)单克隆抗体
WO2009017823A2 (en) * 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
CN101891818B (zh) * 2009-01-16 2012-07-25 中国人民解放军第四军医大学 抗人前列腺特异性膜抗原胞外区单链抗体及其应用
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
SG11201407600UA (en) * 2012-06-19 2014-12-30 Polytherics Ltd Novel process for preparation of antibody conjugates and novel antibody conjugates
US20150290342A1 (en) * 2012-10-24 2015-10-15 Polytherics Limited Drug-protein conjugates
NO2789793T3 (OSRAM) 2012-10-24 2018-01-27
JP6857028B2 (ja) * 2013-03-15 2021-04-14 メモリアル スローン ケタリング キャンサー センター 免疫治療のための組成物および方法
JP6908964B2 (ja) * 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Ｐｓｍａリガンドコンジュゲートによる併用療法
WO2015057250A1 (en) * 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
SG10201913977TA (en) * 2014-05-22 2020-03-30 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
WO2016059377A1 (en) 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
ES2960741T3 (es) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugados y reactivos de conjugación
WO2019173324A1 (en) * 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof

Also Published As

Publication number Publication date
JP2019535232A (ja) 2019-12-12
EP3500595B1 (en) 2024-05-01
CN110049999A (zh) 2019-07-23
ES2983492T3 (es) 2024-10-23
US20190300623A1 (en) 2019-10-03
EP4403226A2 (en) 2024-07-24
JP2022084715A (ja) 2022-06-07
CN110049999B (zh) 2023-12-19
WO2018033749A1 (en) 2018-02-22
EP3500595A1 (en) 2019-06-26
JP7486538B2 (ja) 2024-05-17
EP4403226A3 (en) 2024-10-16
JP7039554B2 (ja) 2022-03-22
US11059903B2 (en) 2021-07-13

Similar Documents

Publication Publication Date Title
IL290457A (en) Antibodies and their conjugates
IL274152B (en) Anti-galectin-9 antibodies and their uses
ZA202101318B (en) Anti-phf-tau antibodies and uses thereof
IL271477A (en) Anti-cd166 antibodies and their uses
IL267942B (en) Anti-cd73 antibodies and uses thereof
IL262497A (en) Anti-il-33 antibodies, compositions, methods and uses thereof
IL317989A (en) Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
IL255526B (en) cd123 antibodies and their conjugates
SG11201808632YA (en) Anti-pacap antibodies and uses thereof
ZA201705935B (en) Cd48 antibodies and conjugates thereof
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
SG11202000660QA (en) Anti-tigit antibodies
IL314808B1 (en) Conjugated compounds and their uses
IL265471A (en) Pulling-oligonucleotide conjugates and their uses
PT3596125T (pt) Anticorpos anti-par2 e suas utilizações
IL273157A (en) Antibodies specific to AXL and their uses
IL272476A (en) Anti-Apelin antibodies and their uses
IL252430B1 (en) Antibodies, uses and methods
IL266082A (en) Anti-chikv antibodies and their use
IL266049A (en) Antibodies against o1 and their uses
IL264417A (en) Anti-o2 antibodies and their uses
GB201712032D0 (en) Antibodies and uses thereof
IL257434A (en) Mrka polypeptides, antibodies, and uses thereof
GB201609866D0 (en) Antibodies, uses thereof and conjugates thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)